All In Biotech

Drug Trial Radar · NCT07038356

Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 536 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

536

Planned (sponsor's estimate)

Start

Dec 8, 2025

Primary completion

Apr 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Christian SchulzeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test the hypothesis that the continuation of empagliflozin during decongestive therapy in the setting of acute decompensated and hospitalized heart failure patients is not inferior compared to therapy cessation during the acute heart failure hospitalization. Randomized treatment (plus standard medical care) in patients with acute decompensated heart failure is one (1) tablet daily of empagliflozin 10 mg or matching placebo during the in-hospital stay (up to a maximum of 30 days), followed by treatment with empagliflozin 10 mg daily after discharge (but no later than day 31) until day 90. The primary outcome measure is the combined hierarchical endpoint of all-cause mortality, heart failure hospitalization and worsening renal function at 90 days after admission. Secondary outcome measures are the effects on urine output, diuretic efficiency, quality-of-life and the need for further administration of diuretics. Participants will * Take one tablet of study medication once daily (day 1 to day 90) * Restrict fluid intake to 1.5 liters of fluid per day and record the daily fluid intake for the study from day 1 to day 6 in the patient diary * Measure the urine output (day 1 to day 6) * Fill in Questionnaires (EQ-5D-3L (3-level version of the EuroQol five dimensional descriptive system), KCCQ-12 (Kansas City Cardiomyopathy Questionnaire comprising 12 items)) on day 0 (Baseline), at hospital discharge, and on day 30

Conditions

  • Acute Decompensated Heart Failure (ADHF)

Interventions

  • Empagliflozin 10 MG Oral Tablet [Jardiance]Drug

    Randomized treatment with 10 mg empagliflozin (Jardiance, one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90

  • PlaceboDrug

    Randomized treatment with placebo (one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Four-step hierarchical composite primary endpoint; win ratio based on the following parameters (day 90): time to all-cause death, number of heart failure events per patient, time to first heart failure event, eGFR decrease from baseline to day 90Time frame: day 90

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Kerckhoff-Klinik GmbH

    Bad Nauheim, Germany · Recruiting

  • Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin

    Berlin, Germany · Recruiting

  • Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik II, Herzzentrum

    Bonn, Germany · Recruiting

  • Herzzentrum Dresden GmbH Universitaetsklinik

    Dresden, Germany · Recruiting

  • Universitaetsmedizin Goettingen

    Göttingen, Germany · Recruiting

  • Universitätsklinikum Halle (Saale), Klinik für Innere Medizin III

    Halle, Germany · Recruiting

  • Universitaetsklinikum Leipzig AöR

    Leipzig, Germany · Recruiting

  • Herzzentrum Leipzig GmbH

    Leipzig, Germany · Recruiting

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

    Mainz, Germany · Recruiting

  • LMU Klinikum Muenchen AöR

    München, Germany · Recruiting

  • Rostock University Medical Center

    Rostock, Germany · Recruiting

  • Jena University Hospital

    Jena, Thuringia, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.